Ramaprasad Srinivasan

Also affiliated with The University of Texas MD Anderson Cancer Center, National Cancer Institute, Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 29 papers. Top paper: “Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease”.

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

New England Journal of Medicine(2021)10.1056/nejmoa2103425

N/A

4.7DataRank · unranked

664 citations

Frede Donskov, Othon Iliopoulos, W. Kimryn Rathmell, Vivek K. Narayan, Benjamin L. Maughan +10 more

TFEB and TFE3 drive kidney cystogenesis and tumorigenesis

EMBO Molecular Medicine(2023)10.15252/emmm.202216877

N/A

1.3DataRank · unranked

61 citations

Angela Zampelli, Letizia Granieri, Claudia Vilardo, Rossella De Cegli, Laura Cinque +18 more

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00389-9

N/A

1.0DataRank · unranked

37 citations

Ane B. Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E. Beckermann, Stéphane Oudard +10 more

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2168

N/A

0.815DataRank · unranked

22 citations

R. Taylor Sundby, Mary Frances Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener +27 more

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

The Lancet Oncology(2025)10.1016/s1470-2045(25)00099-3

N/A

0.741DataRank · unranked

27 citations

Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L Maughan, Stéphane Oudard +9 more

Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines

Genes Chromosomes and Cancer(2021)10.1002/gcc.22940

N/A

0DataRank · unranked

23 citations

Christopher J. Ricketts, Cathy D. Vocke, J. Keith Killian, Hesed Padilla‐Nash, Martin Lang +12 more

18Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes

Abdominal Radiology(2021)10.1007/s00261-021-02999-9

N/A

0DataRank · unranked

10 citations

Anna K. Paschall, Mark A. Ahlman, A. Cahid Civelek, Faraz Farhadi, S. Mojdeh Mirmomen +9 more

Kidney cancer: from genes to therapy

Current Problems in Cancer(2021)10.1016/j.currproblcancer.2021.100773

N/A

0DataRank · unranked

9 citations

Alexis Rompré‐Brodeur, Michael Daneshvar, Roma Pahwa, Ramaprasad Srinivasan, Bradley R. Webster

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2972

N/A

0DataRank · unranked

58 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma

Journal of Experimental & Clinical Cancer Research(2022)10.1186/s13046-022-02416-z

N/A

0DataRank · unranked

13 citations

Janhavi Dubhashi, Anand Singh, Parthav Jailwala, Alexei Lobanov, Craig J. Thomas +10 more

A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4604

N/A

0DataRank · unranked

2 citations

Elad Sharon, Cheryl Ann Pickett-Gies, Lisa Mac, Julia C. Friend, Erin B. Purcell +14 more

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

Journal of Experimental & Clinical Cancer Research(2023)10.1186/s13046-023-02667-4

N/A

0DataRank · unranked

20 citations

Laura S. Schmidt, Kelli M. Wilson, Christopher J. Ricketts, Carole Sourbier, Cathy D. Vocke +23 more

PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell Carcinoma

Urology(2023)10.1016/j.urology.2023.04.035

N/A

0DataRank · unranked

17 citations

Cathy D. Vocke, Christopher J. Ricketts, Zoë Blake, Kristin K. Choo, Deborah L. Nielsen +14 more

Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma

Current Opinion in Oncology(2023)10.1097/cco.0000000000000939

N/A

0DataRank · unranked

6 citations

Yuanquan Yang, Karie Runcie, Ramaprasad Srinivasan, Eric A. Singer, Taylor Goodstein

Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

(2023)10.1158/1078-0432.c.6532368.v1

N/A

0DataRank · unranked

0 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2592

N/A

0DataRank · unranked

28 citations

Eric Jonasch, Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L. Maughan +10 more

Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease

Ophthalmology(2024)10.1016/j.ophtha.2024.05.024

N/A

0DataRank · unranked

16 citations

Ramaprasad Srinivasan, Jodi K. Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen, Anders Kruse +19 more

Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an “outpatient” alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation(2024)10.1038/s41409-024-02380-6

N/A

0DataRank · unranked

0 citations

Ramaprasad Srinivasan, Enkhtsetseg Purev, Emily McDuffee, Tatyana Worthy, Reem Shalabi +9 more

Biomarkers in advanced renal cell carcinoma: current practice and future directions

Current Opinion in Oncology(2025)10.1097/cco.0000000000001138

N/A

0DataRank · unranked

9 citations

Taylor Goodstein, Gabriela Bravo, Ramaprasad Srinivasan, Eric A. Singer, Vivian Wong

Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease

European Urology(2025)10.1016/j.eururo.2025.03.002

N/A

0DataRank · unranked

8 citations

Cathy Anne Pinto, Yanfang Liu, Kristin Choo, Rabindra Gautam, Claire Fox +15 more

Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan

Urologic Oncology Seminars and Original Investigations(2025)10.1016/j.urolonc.2025.10.009

N/A

0DataRank · unranked

3 citations

C. Ricketts, Lidenys O'Brien, Alexandra Lebensohn, Nityam Rathi, Deborah Nielsen +12 more

Metastasectomy outcomes in renal cell carcinoma: insights from hereditary leiomyomatosis and succinate dehydrogenase deficient cohorts

Urologic Oncology Seminars and Original Investigations(2025)10.1016/j.urolonc.2025.07.021

N/A

0DataRank · unranked

1 citations

Rubén Blachman-Braun, Braden Millan, Lauren Loebach, Jaskirat Saini, Ramaprasad Srinivasan +5 more

Corrigendum

Ophthalmology(2025)10.1016/j.ophtha.2024.12.032

N/A

0DataRank · unranked

0 citations

Ramaprasad Srinivasan, Jodi K. Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen, A. Kruse +13 more

Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention

Journal of Clinical Oncology(2020)10.1200/jco.19.02263

N/A

0DataRank · unranked

63 citations

Julie Y. An, Patrick T. Gomella, Rabindra Gautam, Christopher J. Ricketts, Cathy D. Vocke +7 more

Renal surgery following HIF-2α antagonist therapy: Surgical indications, outcomes and growth kinetics

Urologic Oncology Seminars and Original Investigations(2025)10.1016/j.urolonc.2025.06.015

N/A

0DataRank · unranked

0 citations

Braden Millan, Jason Hyman, Nityam Rathi, Jessica Hsueh, Christopher Koller +16 more

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings

Clinical Imaging(2020)10.1016/j.clinimag.2020.06.010

N/A

0DataRank · unranked

25 citations

Moozhan Nikpanah, Faraz Farhadi, Elizabeth C. Jones, Paul Wakim, Andrew J. Dwyer +6 more

Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5004

N/A

0DataRank · unranked

94 citations

Sandeep Gurram, Munjid Al Harthy, Eric A. Singer, Abhinav Sidana, Brian Shuch +14 more

A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.11540

N/A

0DataRank · unranked

5 citations

Jaydira Del Rivero, Fernanda I. Arnaldez, Ramaprasad Srinivasan, Melissa Spencer, Seth M. Steinberg +8 more

Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase–deficient renal cancer

Science Signaling(2021)10.1126/scisignal.abc4436

N/A

0DataRank · unranked

90 citations

Nunziata Maio, Martin Lang, Christopher J. Ricketts, Cathy D. Vocke, Sandeep Gurram +22 more